

FDA Losing Credibility With Public, Own Staff

Half of survey respondents in the agency said they did not think it was headed in the right direction.

BY JOEL B. FINKELSTEIN
Contributing Writer

WASHINGTON — Members of the scientific community have raised a red flag over the apparent increasing influence of money and politics on the supposedly independent and unbiased internal workings of the Food and Drug Administration and other federal watchdog agencies.

In a confidential survey of staff scientists in the FDA's Center for Drug Evaluation and Research, 19% reported being pressured to push through a drug about which they had reservations and 66% said that they were less than wholly confident that the FDA adequately monitors the safety of drugs after they reach the market.

Across the agency, 50% of respondents said they did not believe that the FDA was headed in the right direction, according to the survey by the Union of Concerned Scientists and Public Employees for Environmental Responsibility.

In the words of one staff scientist: "The FDA is presently being stacked at every management level, including the lowest levels, based on those who will support the big companies' agenda, and the im-

plications for safety and efficacy will be felt long into the future."

Such influences have led to a "crisis in public confidence," according to Dr. Steven Nissen, who until last year chaired the FDA's Cardiovascular and Renal Drugs Advisory Committee.

"We have to work a lot harder now ... to keep the politicians out of the science as much as possible and to keep the commercialization of science from coloring everything we see and hear of scientific value," he said at a panel discussion on conflict of interest on government science panels sponsored by the Center for Science in the Public Interest. CSPI is a nonprofit consumer organization focused on food, nutrition, and health issues. It is perhaps best known for its efforts to disclose the nutritional content of fast-food products.

Dr. Nissen criticized the agency's top leaders for "whining incessantly" to Congress about the burden of regulation rather than asking for more authority. "While the American people worry about the safety of drugs, the top FDA leadership tells us we need fast drug approval," he said.

Dr. Nissen said the appointments of Lester Crawford, D.V.M., Ph.D., and Dr.

Andrew von Eschenbach as acting FDA commissioner and Dr. Scott Gottlieb as FDA deputy commissioner for policy also have raised some troubling questions about conflict of interest with the agency, he said. (Dr. Crawford eventually gained Senate confirmation to his position, but resigned shortly thereafter.)

"In his role as director of the National Cancer Institute, [acting commissioner von Eschenbach] must seek FDA approval for human testing or approval of new cancer drugs, an obvious conflict of interest. Even worse, the administration has appointed Scott Gottlieb as deputy commissioner, who came to this job with no regulatory experience, directly from Wall Street where he served as a biotech analyst and stock promoter," Dr. Nissen said.

Also speaking as part of the panel, Dr. Gottlieb refused to address those charges, but defended FDA policy that allows the agency leeway in impaneling advisory committee members who have financial ties to industry.

The advice the FDA receives from advisory committees must span the breadth of both clinical research and clinical practice, he said. "That's the kind of advice that you can only get from people who are heavily engaged in clinical trials."

Dr. Gottlieb also announced FDA plans to revamp the advisory committee guide-

lines, including updated rules that determine whether members need to be recused because of a potential conflict of interest. However, it is unclear how those changes will relieve the concern, both inside and outside the agency, that these panels are being manipulated.

"I've observed that [FDA] management and [drug and device manufacturing] companies have found ways to manipulate this process in favor of approval. These methods are very subtle and would not easily be recognized," recounted one respondent to the survey by the Union of Concerned Scientists.

The anonymous respondent went on to describe these techniques.

Within the FDA, scheduling conflicts can be used to exclude a committee member expected to oppose a drug's approval, and managers have been known to massage presentations to the committee to soften damaging findings. Drug companies have learned that by hiring experts as consultants they can deny FDA access to them, and that by hiring committee members themselves, they can force them to be excluded from voting on a company's drug.

"As advisers, we get the data that is presented to us and ... you can tell where the agency wants you to go," Dr. Nissen said. "The material you get has to be unbiased, and I'm worried that it might not be." ■

CLASSIFIEDS

Also Available at www.clinicalpsychiatrynews.com

UCNS ACCREDITED FELLOWSHIP IN

BEHAVIORAL NEUROLOGY & NEUROPSYCHIATRY DARTMOUTH-HITCHCOCK MEDICAL CENTER AND THE NEW HAMPSHIRE HOSPITAL

PGY 5 fellowship in Behavioral Neurology & Neuropsychiatry available July 1, 2007. Training in the evaluation and management of psychiatric problems related to neurological disease. Special emphasis on the problems of patients with traumatic brain injury, developmental disabilities, dementia, and epilepsy. Inpatient experience on the New Hampshire Hospital Neuropsychiatry Unit and Consultation Service, and outpatient experience in the Dartmouth-Hitchcock Medical Center Neuropsychiatry Clinic. Faculty include neuropsychiatrists, neurologists, and neuropsychologists. Participation in clinical research protocols in epilepsy, dementia, schizophrenia, and traumatic brain injury expected.

Send letter, CV, references to Thomas McAllister, M.D., Director, Section of Neuropsychiatry, Dartmouth-Hitchcock Psychiatric Associates, One Medical Center Drive, Lebanon, NH 03756-0001. (603)650-5824

FELLOWSHIP

POST-DOCTORAL RESEARCH FELLOWSHIP IN CHILD PSYCHIATRY UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE

A post-doctoral research fellowship position is available in our clinical research program focusing on the following areas: the longitudinal study of the characteristics, course, risk factors, psychobiology (including functional magnetic resonance imaging) and treatment of childhood/adolescent affective and anxiety disorders, autism, attention deficit, disruptive disorders and eating disorders.

Our Advanced Center for Interventions and Services Research for Early-Onset Mood and Anxiety Disorders and three program projects (in the Psychobiology of Affective & Anxiety Disorders, Behavior Genetics of Affective/Anxiety Disorders, and the Neurobiology of Autism) provide the opportunity to work and study with some of the country's leading clinical researchers. Potential mentors include:

- | | |
|--|---|
| ♣ David Axelson, M.D. – Bipolar Disorder | ♣ David Kolko, Ph.D. – Conduct Disorders |
| ♣ Boris Birmaher, M.D. – Mood & Anxiety Disorders | ♣ Rolf Loeber, Ph.D. – Conduct Disorders |
| ♣ David Brent, M.D. – Mood & Anxiety Disorders and Suicidal Behavior | ♣ Beatriz Luna, Ph.D. – fMRI |
| ♣ Oscar Bukstein, M.D., M.P.H. – Adolescent Substance | ♣ Nancy Minshew, M.D. – Autism |
| ♣ Bernie Devlin, Ph.D. – Psychiatric Genetics | ♣ Brooke Molina, Ph.D. – ADHD |
| ♣ Walter Kaye, M.D. – Eating Disorders | ♣ James Perel, Ph.D. – Psychopharmacology |
| | ♣ Neal Ryan, M.D. – Mood & Anxiety Disorder |

We seek individuals either with an M.D. who have completed an accredited residency program in general and/or child psychiatry or a Ph.D. in psychology (clinical/quantitative) from an APA-accredited program with a broad-based intellectual background, evident potential for academic/psychiatric research, and ability to think creatively. Must have clinical experience in psychiatric inpatient/outpatient and/or pediatric setting, familiarity with psychiatric nosology and interest in basic or applied research in developmental psychopathology. A high proportion of our graduates have received external funding.

Please submit vita and three letters of recommendation to:

David A. Brent, M.D.
Professor of Psychiatry, Pediatrics and Epidemiology
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic
3811 O'Hara Street, BT 313
Pittsburgh, PA 15213
Email: brentda@upmc.edu
FAX: (412) 246-5344

BEST READERSHIP, LOW COST QUALIFIED LEADS

2007 CLASSIFIEDS

Clinical Psychiatry News
Rates
4 Column Classified Ads
From 1" to 12"
Sizes from 1/48th
of a page
to a full page

For Deadlines and More Information
Contact: Robin Cryan (212) 633-3160
fax your ad to 212-633-3820

Email your ad to:
r.cryan@elsevier.com



Clinical Psychiatry News
Elsevier-Clinical Psychiatry News
360 Park Avenue
New York, NY 10010